These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex. Pickar JH; Mirkin S Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688 [TBL] [Abstract][Full Text] [Related]
4. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss. Komm BS; Mirkin S; Jenkins SN Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044 [TBL] [Abstract][Full Text] [Related]
5. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms. Parish SJ; Gillespie JA Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583 [TBL] [Abstract][Full Text] [Related]
6. Selective estrogen modulators in menopause. Gambacciani M Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250 [TBL] [Abstract][Full Text] [Related]
7. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause. Umland EM; Karel L; Santoro N Pharmacotherapy; 2016 May; 36(5):548-61. PubMed ID: 27027527 [TBL] [Abstract][Full Text] [Related]
8. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms. Kagan R J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213 [TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Pinkerton JV; Pickar JH; Racketa J; Mirkin S Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Lobo RA; Pinkerton JV; Gass MLS; Dorin MH; Ronkin S; Pickar JH; Constantine G Fertil Steril; 2009 Sep; 92(3):1025-1038. PubMed ID: 19635615 [TBL] [Abstract][Full Text] [Related]
11. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials. Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials. Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058 [TBL] [Abstract][Full Text] [Related]
14. Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Mirkin S; Komm B; Pickar JH Womens Health (Lond); 2014 Mar; 10(2):135-46. PubMed ID: 24601804 [TBL] [Abstract][Full Text] [Related]
15. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Mirkin S; Komm BS; Pan K; Chines AA Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989 [TBL] [Abstract][Full Text] [Related]
16. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women. Abraham L; Bushmakin AG; Dragon E; Komm BS; Pinkerton JV Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739 [TBL] [Abstract][Full Text] [Related]
17. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF; J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370 [TBL] [Abstract][Full Text] [Related]